Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group.

[1]  J Bogaert,et al.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Nackaerts,et al.  Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Menten,et al.  Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review. The Leuven Lung Cancer Group. , 1998, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[4]  K. Nackaerts,et al.  Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer - A prospective analysis of 50 cases , 1997 .

[5]  L. Strauss,et al.  Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology. , 1997, The oncologist.

[6]  M. Buyse,et al.  Immunocytochemical markers in stage I lung cancer: relevance to prognosis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Arriagada.  OPTIMIZING CHEMOTHERAPY AND RADIOTHERAPY IN LOCALLY ADVANCED NON–SMALL CELL LUNG CANCER , 1997 .

[8]  K. Nackaerts,et al.  Survival and prognostic factors in resected N2 non-small cell lung cancer: A study of 140 cases , 1997 .

[9]  Guy Marchal,et al.  Multimodality image registration by maximization of mutual information , 1997, IEEE Transactions on Medical Imaging.

[10]  G. V. von Schulthess,et al.  Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. , 1997, Radiology.

[11]  N. Choi,et al.  Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Coleman,et al.  Pulmonary abnormalities and PET data analysis: a retrospective study. , 1997, Radiology.

[13]  V. Lowe,et al.  Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. , 1996, American Journal of Clinical Oncology.

[14]  D. Sugarbaker,et al.  Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2): Analysis of Cancer and Leukemia Group B Protocol 8935 , 1996, Cancer.

[15]  M. Sasaki,et al.  A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma , 1996, Annals of nuclear medicine.

[16]  A. Dowlati,et al.  Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. , 1996, The European respiratory journal.

[17]  T. Olencki,et al.  Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer. , 1995, The Annals of thoracic surgery.

[18]  J. Crowley,et al.  Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Gupta,et al.  PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. , 1995, Chest.

[20]  P. Marsden,et al.  Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer , 1994, The Lancet.

[21]  H. Miyazawa,et al.  PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  M. Kris,et al.  Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Coleman,et al.  Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. , 1993, Radiology.

[24]  M. Kris,et al.  Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. , 1993, The Annals of thoracic surgery.

[25]  J. Clark,et al.  Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. , 1993, European journal of cancer.

[26]  N. Choi,et al.  Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G van Kaick,et al.  Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  C. Perez,et al.  Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. , 1990, Annals of internal medicine.

[29]  Heikki Joensuu,et al.  Florodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors , 1988 .

[30]  N. Martini,et al.  The role of surgery in N2 lung cancer. , 1987, The Surgical clinics of North America.

[31]  J. Cooper,et al.  Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. , 1982, The Journal of thoracic and cardiovascular surgery.

[32]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[33]  T. Naruke,et al.  Lymph node mapping and curability at various levels of metastasis in resected lung cancer. , 1978, The Journal of thoracic and cardiovascular surgery.

[34]  H. Woodard,et al.  Expression of Tissue Isotope Distribution , 1975 .

[35]  H. Woodard,et al.  Letter: Expression of tissue isotope distribution. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.